[3F] Corporate Exhibits

[3F-03T] The strategy to achieve high efficacy and safety in mRNA therapeutics

*Tetsuo Yoshida^1,2, Rena Akahori^2,3, Akiko Yanagiya², Naoki Matsumoto², Daichi Matsuura², Hayato Sato², Hiroaki Murakami², Tomohiro Sawadaishi², Yanwen Feng², Jun Nihira², Satoshi Abe², Kazuyuki Nakashima² (1. Axcelead, Inc. (Japan), 2. ARCALIS, Inc. (Japan), 3. Hitachi, Ltd. (Japan))

Keywords:

mRNA,CDMO,dsRNA,RNA Polymerase,5'CAP

Login required to view

Login is required to view some content.

Log in